The Expanding Therapeutic Perspective of CCR5 Blockade

Gene Editing

(2017) Dale Ando et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV

(2017) Yi Zheng et al.   IMMUNITY

The possible role of CCR5Δ32 mutation in Crimean-Congo hemorrhagic fever infection

(2017) Aydin Rustemoglu et al.   JOURNAL OF MEDICAL VIROLOGY

Refining strategies to translate genome editing to the clinic

(2017) Tatjana I Cornu et al.   NATURE MEDICINE

Opportunities for therapeutic antibodies directed at G-protein-coupled receptors

(2017) Catherine J. Hutchings et al.   NATURE REVIEWS DRUG DISCOVERY

The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation

(2017) Tomohiro Horio et al.   TRANSPLANT IMMUNOLOGY

The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection

(2017) Assunta Venuti et al.   Frontiers in Immunology

Early involvement of cellular stress and inflammatory signals in the pathogenesis of tubulointerstitial kidney disease due to UMOD mutations

(2017) Matteo Trudu et al.   Scientific Reports

Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS

(2016) Manjunath N. Swamy et al.   ADVANCED DRUG DELIVERY REVIEWS

Interfering with CCL5/CCR5 at the Tumor-Stroma Interface

(2016) Vincenzo Bronte et al.   CANCER CELL

CCR5+T-bet+FoxP3+Effector CD4 T Cells Drive AtherosclerosisNovelty and Significance

(2016) Jie Li et al.   CIRCULATION RESEARCH

Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects

(2016) M.M. Pozo-Balado et al.   CLINICAL MICROBIOLOGY AND INFECTION

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design

(2016) Scott Friedman et al.   Contemporary Clinical Trials

Antibodies to watch in 2017

(2016) Janice M. Reichert   mAbs

Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5

(2016) Kayan Tam et al.   mBio

Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis

(2016) Andrea Mencarelli et al.   Scientific Reports

I Am the Berlin Patient: A Personal Reflection

(2015) Timothy Ray Brown   AIDS RESEARCH AND HUMAN RETROVIRUSES

Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development

(2015) Rafael E. Marques et al.   IMMUNOLOGY

Elevated chemokine levels during adult but not pediatric Crimean–Congo hemorrhagic fever

(2015) Mehmet Arasli et al.   JOURNAL OF CLINICAL VIROLOGY

CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape

(2015) Gero Hütter et al.   Viruses-Basel

Maraviroc: a review of its use in HIV infection and beyond

(2015) Georgette Kanmogne et al.   Drug Design Development and Therapy

A Linear Epitope in the N-Terminal Domain of CCR5 and Its Interaction with Antibody

(2015) Benny Chain et al.   PLoS One

CC Chemokine Receptor 5: The Interface of Host Immunity and Cancer

(2014) Carlos Eduardo Coral de Oliveira et al.   DISEASE MARKERS

The potential to target CCL5/CCR5 in breast cancer

(2014) Marco Velasco-Velázquez et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The Inflammatory Chemokine CCL5 and Cancer Progression

(2014) Donatella Aldinucci et al.   MEDIATORS OF INFLAMMATION

CCR5 Controls Immune and Metabolic Functions during Toxoplasma gondii Infection

(2014) Giuliano Bonfá et al.   PLoS One

Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases

(2013) Michela Flego et al.   BMC Medicine

Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial

(2013) Stefano Rusconi et al.   PLoS One

Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex

(2013) Q. Tan et al.   SCIENCE

CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?

(2012) Alicia Gonzalez-Martin et al.   Anti-Cancer Agents in Medicinal Chemistry

In vitro effects of the CCR5 inhibitor maraviroc on human T cell function

(2012) H. Arberas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CCR5 is a receptor for Staphylococcus aureus leukotoxin ED

(2012) Francis Alonzo III et al.   NATURE

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

(2012) Dona L Fleishaker et al.   ARTHRITIS RESEARCH & THERAPY

Resistance to the CCR5 Inhibitor 5P12-RANTES Requires a Difficult Evolution from CCR5 to CXCR4 Coreceptor Use

(2011) Rebecca Nedellec et al.   PLoS One

Engineering of Lactobacillus jensenii To Secrete RANTES and a CCR5 Antagonist Analogue as Live HIV-1 Blockers

(2010) L. Vangelista et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chemokine receptor CCR5: from AIDS to atherosclerosis

(2010) KL Jones et al.   BRITISH JOURNAL OF PHARMACOLOGY

CCL5 as an adjuvant for cancer immunotherapy

(2010) Natalia Lapteva et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Expression of Chemokines and Their Receptors by Human Brain Endothelium: Implications for Multiple Sclerosis

(2009) Eve A. Subileau et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Long-Term Control of HIV byCCR5Delta32/Delta32 Stem-Cell Transplantation

(2009) Gero Hütter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety concerns about CCR5 as an antiviral target

(2009) Amalio Telenti   Current Opinion in HIV and AIDS

Chemotaxis, chemokine receptors and human disease

(2008) Tian Jin et al.   CYTOKINE

A Deletion in the Chemokine Receptor 5(CCR5)Gene Is Associated with Tickborne Encephalitis

(2008) Elin Kindberg et al.   JOURNAL OF INFECTIOUS DISEASES

Genetic Deficiency of Chemokine Receptor CCR5 Is a Strong Risk Factor for Symptomatic West Nile Virus Infection: A Meta‐Analysis of 4 Cohorts in the US Epidemic

(2008) Jean K. Lim et al.   JOURNAL OF INFECTIOUS DISEASES

Role for CCR5 in Dissemination of Vaccinia Virus In Vivo

(2008) R. Rahbar et al.   JOURNAL OF VIROLOGY

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

(2008) Elena E Perez et al.   NATURE BIOTECHNOLOGY

Chemokine receptor antagonists: overcoming developmental hurdles

(2008) Richard Horuk   NATURE REVIEWS DRUG DISCOVERY

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

(2008) Gerd Fätkenheuer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide

(2008) H. Gaertner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rational design of novel HIV-1 entry inhibitors by RANTES engineering

(2008) Luca Vangelista et al.   VACCINE